{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:24:08Z","timestamp":1784543048780,"version":"3.55.0"},"reference-count":74,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Today, we are witnessing a new era for the treatment of hepatitis C with excellent rates of virologic response and very good safety profiles. Among the many classes of direct\u2010acting antivirals, the inhibitors of nonstructural protein 5A are particularly interesting. <jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>5A is a phosphorylated protein with a relevant role in viral replication. <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>5A inhibitors show high potency, very good safety profile and high barrier to resistance. The amazing in vitro effectiveness of this class is associated with great efficacy in clinical trials in combination protocols with antivirals of other classes, with sustained virological response (<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>) obtained in more than 90% of patients. Herein, we sought to review the current knowledge regarding the <jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>5A protease complex inhibitors with special emphasis on clinical efficacy and development of viral resistance.<\/jats:p>","DOI":"10.1111\/jvh.12657","type":"journal-article","created":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T12:23:30Z","timestamp":1481113410000},"page":"180-186","source":"Crossref","is-referenced-by-count":32,"title":["<scp>NS<\/scp>5A inhibitors for the treatment of hepatitis C infection"],"prefix":"10.1111","volume":"24","author":[{"given":"Stefano","family":"Gitto","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine","family":"Gamal","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Andreone","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,1,20]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003258669"},{"key":"e_1_2_8_3_1","unstructured":"Guidelines for the screening care and treatment of persons with hepatitis C infection. Accessed October 3 2016.http:\/\/www.who.com"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2013.08.019"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.80204-0"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.03.003"},{"key":"e_1_2_8_7_1","article-title":"Electronic address eee. EASL recommendations on treatment of hepatitis C 2016","author":"European Association for the Study of the Liver","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.021"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.03.030"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1995.tb00289.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00616-10"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04077"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00253-11"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.018531-0"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.484"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874091X00903010039"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23278"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1203110110"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00215-11"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08960"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/3-540-26397-7_9"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep04765"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i11.2902"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24594"},{"key":"e_1_2_8_25_1","unstructured":"Harvoni (ledipasvir\u2010sofosbuvir) tablets: U.S. prescribing information. Foster City CGS March 2015 (http:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/liver-disease\/harvoni\/harvoni_pi.pdf."},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00052-9"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3092"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1157163"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12524"},{"key":"e_1_2_8_33_1","first-page":"256","article-title":"Ledipasvir\/Sofosbuvir (harvoni): improving options for hepatitis C virus infection","volume":"40","author":"Gritsenko D","year":"2015","journal-title":"Pharm Ther"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0381-2"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)70099-X"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501315"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1373"},{"key":"e_1_2_8_38_1","unstructured":"VIEKIRA PAK[package insert].North Chicago IL:AbbVie Inc."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.045"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12931"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2015.51.5.2332992"},{"key":"e_1_2_8_43_1","unstructured":"KrishnanP TripathiR SchnellG et\u00a0al.Pooled analysis of resistance in patients treated with ombitasvir\/ABT\u2010450\/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials.Presented at: the Annual Meeting of the American Association for the Study of the Liver Diseases (AASLD). Boston MA USA. November 7\u201011 2014."},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04226-14"},{"key":"e_1_2_8_45_1","unstructured":"http:\/\/www.FDA.gov. Accessed 4 October 2016."},{"key":"e_1_2_8_46_1","unstructured":"Bristol\u2010Myers\u2010Squibb.Daklinza (daclatasvir) Summary of Product Characteristics. European Union 2014. Accessed on October 4 2016."},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.24416"},{"key":"e_1_2_8_48_1","unstructured":"HezodeCFH ZoulimF LebrayP et\u00a0al.Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Genotype 3 Patients from a Large French Multicenter Compassionate Use Program. Annu Meet Am Assoc Stud Liver Dis (AASLD) (November 13\u201015 San Francisco) 2015 Abstract 206."},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28473"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28446"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.025"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.10.019"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61059-X"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3868"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535\u2010016\u20101252\u20107"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01209-12"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01874-12"},{"key":"e_1_2_8_58_1","volume-title":"50th Annu Meet Euro Assoc Study Liver Dis.","author":"David Wyles AM"},{"key":"e_1_2_8_59_1","unstructured":""},{"key":"e_1_2_8_60_1","unstructured":"Package Insert. ZepatierTM (elbasvir and grazoprevir). Food and Drug Administration. 2016."},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ722"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.009"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2016.52.7.2510258"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61795-5"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61793-1"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0785"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00349-9"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201300343"},{"key":"e_1_2_8_69_1","unstructured":"ZEPATIER.Highlights of prescribing information."},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512614"},{"key":"e_1_2_8_73_1","unstructured":"EPCLUSA\u00ae.Highlights of prescribing information.http:\/\/www.gilead.com\/~\/media\/files\/pdfs\/medicines\/liver-disease\/epclusa\/epclusa_pi.pdf?la=en."},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00763-16"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-016-9748-z"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12657","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T12:26:42Z","timestamp":1696163202000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,20]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/jvh.12657"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12657","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,20]]}}}